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Background: Scaffolding of signaling proteins to GPCRs may increase signaling efficiency and spatial fidelity.
Results:PhospholipaseC (PLC)3 binding directly toM3muscarinic receptor intracellular loops involves a non-canonical PDZ
interaction.
Conclusion:M3 muscarinic receptor binding to PLC3 optimizes interactions with substrate and G protein activator.
Significance: Scaffolding of PLC enzymes to GPCRs may be important for spatial signal specificity and efficacy.
Phospholipase C (PLC) enzymes are activated by G pro-
tein-coupled receptors through receptor-catalyzed guanine
nucleotide exchange on G heterotrimers containing Gq
family G proteins. Here we report evidence for a direct interac-
tion between M3 muscarinic receptor (M3R) and PLC3. Both
expressed and endogenousM3R interacted with PLC in coim-
munoprecipitation experiments. Stimulation of M3R with car-
bachol significantly increased this association. Expression of
M3R in CHO cells promoted plasma membrane localization of
YFP-PLC3. Deletion of the PLC3 C terminus or deletion of
the PLC3 PDZ ligand inhibited coimmunoprecipitation with
M3R and M3R-dependent PLC3 plasma membrane localiza-
tion. Purified PLC3 bound directly to glutathione S-transfer-
ase (GST)-fused M3R intracellular loops 2 and 3 (M3Ri2 and
M3Ri3) as well asM3RC terminus (M3R/H8-CT). PLC3 bind-
ing to M3Ri3 was inhibited when the PDZ ligand was removed.
In assays using reconstituted purified components in vitro,
M3Ri2, M3Ri3, and M3R/H8-CT potentiated Gq-dependent
but not G-dependent PLC3 activation. Disruption of key
residues in M3Ri3N and of the PDZ ligand in PLC3 inhibited
M3Ri3-mediated potentiation.We propose that theM3musca-
rinic receptor maximizes the efficiency of PLC3 signaling
beyond its canonical role as a guanine nucleotide exchange fac-
tor for G.
Gprotein-coupled receptors (GPCRs)2 are seven-transmem-
brane proteins that relay information fromextracellular signals.
Upon activation by ligand binding, GPCRs catalyze guanosine
diphosphate (GDP) dissociation from the G heterotrimer
substrate; guanosine triphosphate (GTP) binding to G follows
and leads to functional dissociation of G from G and effec-
tor enzyme activation (1, 2). Activation of effector enzymes
initiates specific signaling cascades that regulate cell physiol-
ogy. Hydrolysis of phosphatidylinositol 4,5-bisphosphate
(PIP2) to diacylglycerol and inositol 1,4,5-trisphosphate (IP3) by
G protein-responsive phospholipase C (PLC) is a principal
signal transduction pathway activated by GPCRs (3–5).
Classically, effector activation byGproteins is thought to rely
on random collision coupling between activated, diffusible G
protein and target effector following receptor activation (1). In
recent years, this paradigm has been extensively challenged.
Biochemical evidence and studies in live cells have led to an
emerging view that some G proteins are precoupled to recep-
tors (6–13). There are also reports of stable complexes between
GPCRs and other effectors such as G protein-sensitive inward
rectifier potassium channels (14–18). Detailed studies of the
Gq-PLC signaling system revealed a novel paradigm in G pro-
tein signaling, called kinetic scaffolding, where the intrinsic Gq-
GTPase stimulating function leads to spatially and temporally
focused PLC activation (19, 20).
Phospholipase C is often found in physical complexes with
GPCRs through interactions with intermediary scaffolds. One
such class of scaffolds is postsynaptic density-95/disc large/
ZO-1 (PDZ) domain-containing proteins. PDZ domains are
independently folded protein modules that specifically bind
and recognize PDZ ligand consensus sequences at the extreme
C terminus of target proteins (21, 22). PDZ domain-containing
proteins generally have multiple individual PDZ domains and
thus can scaffold target proteins together (21–23). All PLC
isoforms have PDZ ligand motifs at their C terminus with a
consensus sequence (X(S/T)X(V/L)-COOH) (21, 22). Examples
of PLC-interacting PDZ scaffolds are NHERF1, NHERF2,
PDZK1, and Shank2 that organize specific signaling complexes
with parathyroid hormone receptor PTH1R (24), lysophospha-
tidic acid receptor LPA2R (25), somatostatin receptor (26), and
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metabotropic glutamate receptor mGluR1 (27), respectively
(21, 22). There is increasing recognition that PDZ-dependent
organization is required for receptor-dependent activation of
PLC (25, 28); however, in a classical collision-couplingmodel,
one would not expect physical scaffolding to be required for
GPCR-dependent effector activation.
In the present studies, we investigated a direct interaction
between the M3 muscarinic receptor (M3R), a prototypical
Gq-coupled receptor, and its effector enzyme, PLC3. We
demonstrate here that M3R binds to PLC3 and drives plasma
membrane enrichment of PLC3 in cells. Interaction sites for
direct protein-protein binding that alter the efficiency ofG pro-
tein-dependent PLC activation are also defined. Taken
together, the direct binding interaction between M3R and
PLC3 may represent a regulatory mechanism for PLC signal
output beyond receptor-stimulated nucleotide exchange on
Gq.
EXPERIMENTAL PROCEDURES
Materials—n-Dodecyl -maltoside was purchased from
Dojindo Molecular Technologies. Resins for purification were
from GE Healthcare (glutathione-Sepharose 4B), Qiagen (Ni-
NTA-agarose), and Genscript (protein G-agarose). Antibodies
were from Covance (MMS101R, monoclonal HA.11 anti-HA
ascites), a generous donation from Dr. J. Wess (anti-M3R
directed against its last 18 amino acids (29, 30)), from Sigma
(G7781, anti-glutathione S-transferase), from Santa Cruz Bio-
technology (sc-385, anti-Golf antibody), and from R&D Sys-
tems (anti-human PLC3 at Lys27–Leu246). For PLC3 and
PLC1 with an intact C terminus, B521 and B517, respectively,
were used (31). For Gq and G, WO82 (32) and B600 (33),
respectively, were used. For Gs, 584 antiserum was used (33).
Lipofectamine 2000 (Invitrogen) was used for all transient
transfections according to the manufacturer’s instructions.
L--Phosphatidylinositol 4,5-bisphosphate (brain, porcine) and
L--phosphatidylethanolamine (liver, bovine) were from
Avanti Polar Lipids. [Inositol-2-3H]phosphatidylinositol 4,5-bi-
sphosphate ([3H]PIP2) was from PerkinElmer Life Sciences.
M3R Constructs—3xHA-M3R (human, 1–590) for protein
expression was obtained from cDNA.org. 1xHA-M3R (rat,
1–589) in pCD vector (34) was a gift fromDr. J.Wess (National
Institute of Diabetes and Digestive and Kidney Diseases,
National Institutes of Health) and was only used as template to
generate fragment constructs of M3R intracellular loops fused
with glutathione S-transferase (GST) in pGEX4T2 (GEHealth-
care). To allow for purification ofGST fusion proteins via aHis6
tag, an oligonucleotide dimer encoding the tag was inserted
into pGEX4T2 between SalI- and NotI-cut sites. Each M3R
loop was defined as follows: i1 (91–103), i2 (164–183), i3
(i3N 252–389 (10), a gift from Dr. S. Lanier of Medical Uni-
versity of South Carolina; i3M  352–469; i3C  389–491),
and H8-C terminus (CT) (547–589). Subfragments of M3Ri3N
were defined as described in Fig. 6. Each fragment was inserted
between EcoRI- and SalI-cut sites in the modified pGEX4T2,
resulting in an N-terminal GST tag and a C-terminal His6 tag.
PLC3 Constructs—PLC3 (human, 1–1234) in pBluescript
was moved into pciNeo vector (Promega) for mammalian
expression and into pFastbacHTb vector (Invitrogen) for bacu-
loviral insect cell expression between EcoRI and SalI sites. To
generate deletion/mutant constructs at the extremeC terminus
of human PLC3, fragments were generated by PCR flanked by
a native 5 KpnI site (nucleotides 2090–2095) and 3 SalI site
and ligated into vector with a purified N-terminal fragment
digested with EcoRI and KpnI. Deletions were made by remov-
ing the PLC3 PDZ consensus motif NTQL at 1231–1234
(PDZ). A larger deletion from the C terminus (1–886, CT)
was made by PCR to generate a fragment flanked by EcoRI and
SalI for ligation into pciNeo. YFP-PLC3 (rat) full length (FL),
pleckstrin homology (PH) (1–147), C2 (712–809), and CT
(845–1234) in pEYFP-C1 (Clontech) were generated as
described previously (35). To create PDZ versions of PLC3
FL and PLC3 CT, fragments were generated by PCR flanked
by a native 5 HindIII site (nucleotides 2531–2536) and 3
EcoRI site for vector ligation. GFP-PLC3CT was con-
structed in pciNeo with a NheI/EcoRI-digested fragment
encoding for enhancedGFP frompEGFP-C3 (Clontech) and an
EcoRI/SalI-digested PLC3CT fragment (human). Primers
and sequencing results from regions generated by PCR are
available upon request.
Protein Expression and Purification—All buffers for protein
purification were ice-cold and supplemented with protease
inhibitor mixture (133 M phenylmethylsulfonyl fluoride, 21
g/ml 1-chloro-3-tosylamido-7-amino-2-heptanone and L-1-
tosylamido-2-phenylethyl chloromethyl ketone, 0.5 g/ml
aprotinin, 0.2 g/ml leupeptin, 1 g/ml pepstatin A, 42 g/ml
N-p-tosyl-L-arginine methyl ester hydrochloride, 10 g/ml
soybean trypsin inhibitor).
Reported protein concentrations were quantified using an
amido black protein assay. Protein purity was estimated by ana-
lyzingCoomassie-stained protein gels using band densitometry
functions in ImageJ.
Induction and Purification of GST Fusion Proteins—GST-
M3R loop fusion proteins (GST-M3Ri1, GST-M3Ri2, GST-
M3Ri3N/M/C, and GST-M3RCT) were transformed into
BL21(DE3) Escherichia coli. BL21 Rosetta strain was used for
some constructs that were otherwise difficult to express. For
each protein, up to 3-liter cultures were grown in LB/carbeni-
cillin and induced at A600 0.50 with 100 M isopropyl -D-
thiogalactopyranoside for 1 h at 37 °C. Cells were pelleted and
then resuspended in 1 PBS. The pellets were then frozen with
liquid nitrogen for storage at 80 °C. Samples were thawed,
resuspended in lysis buffer (50 mM Hepes, pH 7.4, 150 mM
NaCl, 5% glycerol, 10 mM -mercaptoethanol, 15 mM imidaz-
ole, and 30mgof lysozyme/liter of culture) followed by addition
of 1mg of DNase I/liter of culture and 10mMMgCl2. To enrich
for fully translated proteins, purificationwas achieved by taking
advantage of the C-terminal His6. Supernatant was collected
after 100,000  g ultracentrifugation and loaded onto a pre-
equilibrated 1-ml column ofNi-NTA resin. The loaded column
waswashedwith 600mMNaCl, re-equilibrated, and elutedwith
100–250 mM imidazole. PD-10 columns (GE Healthcare) were
used to equilibrate purified proteins in 50 mM Hepes, pH 7.2,
100 mMNaCl, and 1 mM EDTA. The proteins were snap frozen
and stored at80 °C in aliquots.
For the screening of M3Ri3Na single alanine mutants, gluta-
thione affinity chromatography was used. Protein expression
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was carried out with 25 ml of BL21 cultures. Cell lysis and
supernatant extraction were performed as described above
except with a proportional reduction in scale. Each protein
extract was applied to pre-equilibrated 50% glutathione-Sep-
harose slurry (100 l) for 3 h. Resin washing was performed
essentially as described above exceptwith bufferswithout imid-
azole addition. The partially purified proteins were stored on
ice in 50 mM Hepes, pH 7.2, 100 mM NaCl, and 1 mM EDTA.
Protein stoichiometry was quantified by Coomassie staining of
15% SDS-PAGEwith the inclusion of pure protein standards of
known concentration. The protein amount of eachmutant was
normalized to the fully translated GST fusion protein band.
Expression and Purification of G Protein Subunits—Expres-
sion andpurification ofGproteinsq ors/olf were performed
using Ric-8A or Ric-8B affinity chromatography, respectively,
as described previously (36).
Expression and Purification of PLC3 Proteins—Purification
of PLC proteins was essentially as described previously (37)
with minor modifications. Briefly, His6 N-terminally tagged
PLC3 protein and variants were expressed in 250 ml of High
Five cells infected (at 2 106/ml) with freshly amplified bacu-
lovirus at a multiplicity of infection of 5. 48 h after infection, a
collected cell pellet was resuspended in 50 mM Hepes, pH 8.0,
0.1 mM EGTA, 0.1 mM EDTA, 0.1 mM dithiothreitol, and 100
mMNaCl. The suspension was subjected to four cycles of liquid
nitrogen freeze/thaw. The NaCl concentration was adjusted to
1 M (resupplementedwith protease inhibitors), and themixture
was then ultracentrifuged at 140,000 g. The supernatant was
diluted 5-fold with buffer A (10 mM Hepes, pH 8.0, 0.1 mM
EGTA, 0.1 mM EDTA, 0.5% polyoxyethylene 10-lauryl ether
(C12E10), and 10 mM -mercaptoethanol) and recentrifuged.
The resulting supernatant was loaded onto a pre-equilibrated
4-ml Ni-NTA column. The column was washed with 20 col-
umn volumes of buffer A supplemented with 15 mM imidazole
and 800 mM NaCl. The protein was eluted with buffer A sup-
plemented with 50 mM NaCl and 125 mM imidazole. The yield
was 40 mg of purified protein/liter of High Five culture.
PD-10 columns were used to equilibrate purified proteins in 50
mM Hepes, pH 8.0, 300 mM NaCl, 2 mM dithiothreitol, 0.1 mM
EGTA, and 0.1 mM EDTA. No further purification steps were
deemed necessary to produce80% pure protein.
Laser Confocal Microscopy—Chinese hamster ovary (CHO)
cells were plated on 35-mm dishes at1⁄4 confluence. The fol-
lowing day, they were transiently transfected with YFP/GFP-
PLC3 constructs either with pciNeo vector or 3xHA-M3R
(500 ng of each per dish for a total of 1 g). Prior to live cell
imaging, medium was replaced 18 h after transfection with
imaging buffer (Hanks’ balanced salt solution containing 5.5
mM glucose, 0.56 mM MgCl2, 4.7 mM KCl, 1 mM Na2HPO4, 10
mM Hepes, and 1.2 mM CaCl2, pH 7.4). The following settings
were used: for enhancedGFP, excitation, 488 nm; emission, 510
nm; for enhanced YFP, excitation, 515 nm; emission, 527 nm. z
stacked (one stack 1m) images were acquired directly from
each dish using an Olympus FV1000MP microscope in confo-
cal mode with a LUMPLFL 40 0.8 numerical aperture W
(Olympus) lens. A complete z stack was taken for every field of
view from the top to the bottom of cells.
For estimation of the plasmamembrane/cytosol ratio of pro-
tein distribution, regions of interest were selected from the
same z level either along the entire edge of a cell for plasma
membrane or from those in the body of the cell excluding the
nucleus for cytosol. Mean fluorescence intensities within each
region of interest were measured using Olympus Fluoview ver-
sion 2.0. A z level with the highest fluorescence intensity at the
plasma membrane edge was chosen for analysis and for repre-
sentative images. Because contribution of fluorescence from
the cytosol was not subtracted, a ratio value of 1 does not indi-
cate a 1:1 distribution of fluorescence between plasma mem-
brane and cytosol; rather, it represents the baseline value of
fluorescence distribution for cytosol-localized proteins.
Approximately two to six cells were visible per field of view.
Fluorescence ratios were calculated for all cells in every field of
view captured for each experimental group. At least 20 inde-
pendently acquired images from three separate transfections
were analyzed for each condition. Rounded cells (height more
than 20m), indicative of poor health, were discarded from the
analysis. Where indicated, a blinded observer (unaware of the
experimental conditions behind each image) scored cells with
plasma membrane distribution of fluorescence from entire
image data sets. For this purpose, the order of images was ran-
domly shuffled.
Each representative micrograph at one z plane is supple-
mented with a line profile analysis below. Fluorescence inten-
sities were measured along points a to b and plotted as a func-
tion of distance AB.
Receptor Immunocytochemistry—CHOcells were grown on a
35-mm dish at1⁄3 confluence. The following day, each dish of
cells was transiently transfected with YFP-PLC3 and/or
3xHA-M3R. Empty pciNeo vector was added to equalize
between experimental groups to a total plasmid load of 1 g.
Cells were analyzed the next day by confocal microscopy as
described above. Immediately prior to live cell imaging, surface
3xHA-M3R in these cells was stained with anti-HA antiserum.
Briefly, PBS-washed cells were incubated with anti-HA anti-
body (1:2000) in Hanks’ balanced salt solution with 15 mM
Hepes, pH 7.4 for 1 h at room temperature followed by incuba-
tion with Alexa Fluor 546 anti-mouse antibody (1:1000) for 30
min. Following each incubation step, the cells were washed
three times with 1 PBS. Green and red fluorescence were
acquired using separate laser excitations. Merged fluorescent
images were generated by ImageJ using the Merge Channels
function. The same optical and digital settings for either green
or red channels were applied to all experimental groups.
GST Fusion Protein Pulldown Assay—Purified PLC3 and
variant proteins weremixedwithGST-His6 or GST-M3R loops
in binding buffer (20 mM Hepes, pH 8.0, 1 mM EDTA, 0.1%
polyoxyethylene 10-lauryl ether (C12E10), 2 mM dithiothreitol,
and 150mMNaCl). Equal amounts of GST fusion proteins were
added at 300 nM as determined by Coomassie staining. The
total reaction volume was 500 l. Unless otherwise indicated,
PLC3was added at 10 nM. For pulldown ofGprotein subunits,
30 nM purified Gq, Gs-long, Golf, and G12 were added.
Reactions were incubated by rotating for 1 h at 4 °C. Prior to
addition, glutathione-Sepharose beads were preblocked in
binding buffer supplemented with 0.1% bovine serum albumin
Muscarinic Receptor Interactions with PLC
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(Roche Applied Science) and thenmade into a 50% slurry. 20l
of slurry was incubated with each reaction for 2 h at 4 °C. Beads
were collected by centrifugation at 100  g for 2.5 min at 4 °C
and washed three times with binding buffer. Bound proteins
were eluted from the beads by the addition of 2 loading sam-
ple buffer, boiled at 95 °C for 5min, resolved by SDS-PAGE, and
detected by Western blot. 8% SDS-PAGE was used to resolve
PLC3. 12%SDS-PAGEwas used to resolveGprotein subunits.
For internal GST loading controls, 15% SDS-PAGEwas used to
resolve GST fusion proteins.
Coimmunoprecipitation of Transiently Transfected Proteins—
PLC3 and variant constructs were cotransfected with 3xHA-
M3R in adherent HEK293 cells seeded on poly-D-lysine-coated
dishes (1 g of each construct per dish). In some experiments
where indicated, pciNeo empty vector was cotransfected with
PLC3 in place of 3xHA-M3R as a negative control. 48 h after
transfection, cells were washed and then lysed in 0.1% n-dode-
cyl -D-maltoside in 1 PBS with protease inhibitors. The
lysate was subjected to 100,000  g ultracentrifugation for 20
min at 4 °C. The supernatant was collected and immunopre-
cipitated with anti-HA antibody.Where indicated, no antibody
addition was used as a negative control. Other controls includ-
ing immunoselectionwithHA antibody plusHA-blocking pep-
tide or with myc antibody were performed (data not shown)
and yielded similar results as no antibody addition. Protein
G-agarose was added to incubate with the lysate for 2 h. The
resin was then washed two times in lysis buffer and finally
resuspended in 2 loading sample buffer to be boiled. Eluted
proteins from the immunoprecipitated resin were analyzed by
SDS-PAGE and subsequent immunoblotting. 8% SDS-PAGE
was used to resolve PLC3 and HA-tagged M3R.
Coimmunoprecipitation of Native M3R-PLC Complex—Rat
lungs were disrupted and then homogenized in ice-cold lysis
buffer (1% n-dodecyl -D-maltoside, 20 mMHepes, pH 7.4, 137
mM NaCl, and 2 mM EDTA with protease inhibitors) with an
Ultra Turrax homogenizer at 1-s pulse intervals at 22,000 rpm.
Proteins were quantified using an amido black dye assay. 5 mg
of total protein was used for each immunoprecipitation. For
M3R immunoprecipitation, 1 g of anti-M3R antibody was
used (30). For PLC3 immunoprecipitation, 1 l of B521 anti-
serumwas used (31). After antibody addition, the samples were
incubated for 2 h with Dynal protein G beads, washed three
times in lysis buffer at 0.1% n-dodecyl -D-maltoside, and
resuspended in sonication buffer (50 mM Hepes, pH 7.2, 3 mM
EGTA, 80 mM KCl, and 1 mM DTT). Each sample was further
diluted in a solution supplemented with albumin and reconsti-
tuted with purified Gq and phospholipid vesicles containing
[3H]PIP2 as described in the next section. The reaction was
initiated by the addition of 150 nM free calcium. For Gq
preactivation, GDP and aluminum fluoride (a mixture of alu-
minum chloride and sodium fluoride) were added as described
in the next section. The reaction was allowed to proceed for 30
min. Free [3H]IP3 from each sample was measured by liquid
scintillation counting (36).
Phospholipase C Activation in Reconstituted Vesicles—PLC
substrate was composed of 50 M phosphatidylethanolamine,
25 M PIP2, and [inositol-2-3H]PIP2 at 6–8000 cpm/assay. For
measuring PLC activity associated with native M3R complex,
vesicles consisting of 100Mphosphatidylethanolamine and 25
M PIP2 were used. The vesicles were prepared as described
previously (38). Gq was diluted in buffer containing 20 mM
Hepes, pH8.0, 170mMNaCl, 11mMCHAPS, 1mMEDTA, 1M
GDP, and 1mMDTT. Final CHAPS concentrationwasmade no
higher than 300 M (39). To activate Gq, each reaction was
supplementedwith 10mMNaF and 30MAlCl3 (36). For assays
containing G, 0.15% (w/v) -octyl glucoside (final assay con-
centration) was included (36). Purified Gq-GDP-AlF4 and
G were added at 30 nM unless otherwise indicated. Purified
PLC proteins were added at 10 ng per reaction (1 nM). 1.5
mMCaCl2 (150 nM free Ca2) was added to initiate each reac-
tion, and then the sampleswere incubated at 30 °C for 45min.A
blank set of samples without CaCl2 addition was also included.
Reactions were terminated and then analyzed as described pre-
viously (36). All assays for PLC activity were carried out within
conditions where IP3 production and time were linearly corre-
lated. For concentration-response curves shown, collected data
were analyzed using GraphPad Prism 6.0 and fit using the
log(agonist) versus response function with variable Hill slope.
Statistical Analysis—Unless otherwise stated, analysis of
variance of at least three independent experiments was per-
formed with Bonferroni post-test using GraphPad Prism 6.0 to
determine levels of significance. Error bars indicate S.E. * indi-
cates p	 0.05, and *** indicates p	 0.001 or p	 0.0001.
RESULTS
The M3 Muscarinic Receptor Binds to Phospholipase C3—
Todeterminewhether PLC3 could form a complexwithM3R,
an N-terminal HA epitope-tagged M3R was coexpressed in
HEK293 cells with PLC3, extracted, and immunoprecipitated
with an anti-HA antibody. Immunoprecipitations were ana-
lyzed by SDS-PAGE and immunoblotting for associated
PLC3. PLC3 was detected in the HA immunoprecipitate
only ifHA-M3Rwas expressed (Fig. 1A). To determinewhether
M3R activation could alter association with PLC3, cells
expressing HA-M3R and PLC3 were treated with carbachol
for 5min followed by cell lysis (Fig. 1A, labeled with *), HA-spe-
cific immunoprecipitation, and immunoblotting for PLC3.
Treatment with carbachol led to a 2–3-fold (2.83 
 0.65-fold
from five experiments, p  0.009) increase in PLC3 associa-
tion with HA-M3R (Fig. 1A).
To demonstrate an M3R-PLC protein complex in a native
system, proteins were extracted from rat lung tissue (enriched
in native M3R and PLC3) and immunoprecipitated with anti-
M3R antibody (29, 30). No agonists were added. Detection of
PLC3 in these immunoprecipitates by immunoblotting is dif-
ficult because of the relatively low abundance of the two pro-
teins in native tissues. As a sensitive approach to detecting PLC,
immunoprecipitated samples were assayed for associated PLC
enzymatic activity. WithM3R immunoprecipitation, there was
significantly more associated PLC activity compared with that
in the absence ofM3Rantibody (Fig. 1B). ThisM3R-boundPLC
is likely a PLC isoform because it was activated by purified
Gq-GDP-AlF4. The proportion of Gq-GDP-AlF4-activat-
able PLC associated with M3R was1⁄3 of the total PLC3 that
could be precipitated directly with a PLC3-specific antibody.
Muscarinic Receptor Interactions with PLC
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This suggests that, as expected, not all of the PLC in tissues is
associated with M3R.
M3RPromotes PLC3 Localization to the PlasmaMembrane—
To determine whether expression of M3R could alter the
subcellular localization of PLC3, M3R was coexpressed with
YFP-PLC3 in CHO cells, which do not express muscarinic
receptors. The distribution of YFP-PLC3 fluorescence at the
cell periphery containing the plasma membrane (PM) relative
to the cytosol was analyzed. Previous data have shown that
YFP-PLC3 is cytosolic (35) consistent with the data in Fig. 1C.
M3R coexpression significantly increased PM fluorescence rel-
ative to cytosolic fluorescence of YFP-PLC3 (Fig. 1,C andD; in
blinded analysis, 5 of 100 cells hadYFP-PLC3 PM localization;
when M3R was coexpressed, 102 of 177 cells showed YFP PM
localization). In contrast, YFP-PLC2 fluorescence remained
entirely cytosolic with M3R expression. This supports the
notion that PLC3 binds toM3Rand suggests that one function
of this interaction is to localize PLC3 to the plasmamembrane
near its substrate. Because an agonist was not included in these
experiments, the data imply that PLC3 can be prebound to the
receptor prior to activation.
To confirm colocalization of YFP-PLC3 with M3R at the
PM, cells were transfected with HA-M3R, YFP-PLC3, or both
(Fig. 1E). Cells were stained with anti-HA antibody and imaged
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for YFP and anti-HA in separate channels. In the absence of
M3R, YFP-PLC3 (Fig. 1E, top panels) was cytosolic, and M3R
alone was at the PM (Fig. 1E, middle panels). When expressed
together, a significant proportion of the YFP-PLC3 fluores-
cence colocalized at the PM with HA-M3R (Fig. 1E, bottom
panels), consistent with the idea that PLC3 localization to the
PM is due to association with M3R.
M3R Interactions with PLC3 Involve the PLC3 CTerminus
and the PLC3PDZLigand—To identify regionswithin PLC3
(Fig. 2A) involved in M3R-directed membrane enrichment, we
analyzed the PM localization of three PLC3 domains
expressed as fusions with YFP: YFP-PLC3 PH domain, YFP-
PLC3 C2 domain, and YFP-PLC3 CT. Of the three frag-
ments tested, only PLC3 CT (845–1234) showed an enrich-
ment of PM fluorescence withM3R coexpression (Fig. 2, B and
C). PLC3 CT alone also bound somewhat to membranes (Fig.
2, B and C), consistent with previous findings (35), suggesting
that this domain has an intrinsic affinity for membranes that is
masked in the holoenzyme.
The PLC3 CT also bound to M3R. Cells were transfected
with HA-M3R and YFP-PLC3 CT followed by extraction and
precipitation with or without inclusion of an anti-HA antibody
(Fig. 2D). PLC3 CTwas significantly enriched in samples pre-
cipitatedwith the anti-HA antibody. These results indicate that
M3R can interact with the C terminus of PLC3.
To determine whether the C terminus of PLC3 is required
for interaction with M3R, M3R was coexpressed with GFP-
PLC3 (1–886) (PLC3CT) with the C terminus deleted.
PLC3CT localization was cytosolic and did not change with
M3R expression (Fig. 3, A, left panel, and B). Association of
PLC3CT with M3R was also assessed by coimmunoprecipi-
tation. In contrast to full-length PLC3, PLCCT was not
enriched in anti-HA immunoprecipitates (Fig. 3C). Thus, the C
terminus of PLC3 is required for interaction with M3R.
PLC3 contains a type I PDZ ligand (1231–1234) at its C
terminus. To determine whether the PDZ ligand in PLC3 is
important for interactions with M3R, YFP-PLC3PDZ with
deletion of theC-terminal four-amino acid PDZ ligand (Fig. 3A,
right panels) was transfected with and without M3R. In the
absence of the PDZ ligand, no M3R-dependent recruitment to
the PM was observed. YFP-PLC3PDZ was also transfected
with HA-M3R, and interactions were examined by coimmuno-
precipitation (Fig. 3D). Although the background binding was
higher for this construct, there was no significant coprecipita-
tion of YFP-PLC3PDZwithHA-M3R. These results demon-
strate a critical role for the PDZ ligand of PLC3 in binding to
M3R and driving M3R-dependent PM localization of PLC3.
PLC3 Binds Directly to Intracellular Loops of M3R—The
M3 muscarinic receptor does not contain a PDZ ligand on its
C-terminal tail nor does it contain a PDZ domain, so a canon-
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FIGURE 2. Plasmamembrane localization of PLC3 C terminus depends on M3R expression and binding. A, primary structure of PLCwith PH domain
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ical PDZ scaffold could not mediate the interaction described
here. To determine whether PLC3 can bind to M3R through
direct protein-protein interaction and to characterize the intra-
cellular surface of M3R involved in PLC3 interactions, the
intracellular loops of M3R were expressed and purified as
fusionswithGST. Purified PLC3 bound directly toM3R intra-
cellular loop 2 (M3Ri2), various subfragments of loop 3
(M3Ri3), and the full C-terminal tail (M3R/H8-CT) (Fig. 4A).
The full C-terminal tail immediately distal to TM7 is composed
of helix 8 (H8) parallel to the membrane followed by the
remainder of the CT. Neither H8 nor CT alone bound to
PLC3, suggesting that binding requires both domains or that
both domains are required for proper folding of this region.
Binding of PLC3 to M3R Third Intracellular Loop—The
M3Ri3 is large relative to other typical GPCR intracellular loops
(240 amino acids) and was thus divided into subfragments for
analysis. Within M3Ri3, the strongest apparent binding was to
M3Ri3N. To further define the interaction regions within this
domain, two overlapping fragments of M3Ri3N (depicted in
Fig. 4B) were expressed as GST fusion proteins and tested for
binding to purified PLC3. Although PLC3 binding was
observed at all M3Ri3 N-terminal fragments, the strongest
binding was at residues 252–322 (Fig. 4C). Because M3Ri3N
had weaker binding than theM3Ri3Na subfragment, the larger
construct could contain an element inhibitory toward binding
of PLC3.
To determine whether the PLC3 C terminus and PDZ
ligand are involved in direct interactions with this region,
M3Ri3Na was tested for binding to purified PLC3,
PLC3CT, and PLC3PDZ. Complete disruption of bind-
ing was achieved with deletion of the entire PLC3 CT (Fig.
4D). Removal of PDZ ligandweakened but did not eliminate the
interaction (Fig. 4D). Thus, results using purified proteins
essentially recapitulate the data fromM3R-dependent localiza-
tion and coimmunoprecipitation experiments. This direct
binding toM3R involvesmultiple intracellular loop regions and
requires the C terminus of PLC3 and its PDZ ligand.
Intracellular Loops of M3 Muscarinic Receptor Specifically
Enhance Gq Signaling—To determine how binding of M3R
intracellular loops influences PLC3 signaling, the effects of
M3R loop fragments on G protein-dependent PLC3 activa-
tion were assayed in a purified reconstituted system. Gq-stim-
ulated PLC3 activity was assayed using phospholipid vesicles
containing PIP2 substrate and purified Gq fully activated by
GDP-AlF4 (38). Strikingly, M3Ri2, M3Ri3N, and M3R/H8-CT
potentiated PLC3 activation by Gq-GDP-AlF4 in a concen-
tration-dependent manner with different efficacies and poten-
cies (Fig. 5A). M3Ri1 and M3Ri3M, which do not bind to
PLC3, did not have any significant effect (Fig. 5A). Conversely,
M3Ri3C bound to PLC3 but did not potentiate Gq activa-
tion, indicating that binding to PLC3 is not necessarily suffi-
cient to potentiate its activation by Gq. PLC activity in the
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FIGURE 3. Enrichment of PLC3 at plasmamembrane byM3R and full binding of PLC3 toM3R require the PDZ ligand at the extreme C terminus of
PLC3. A, deletion of PDZ ligand (NTQL, residues 1231–1234) in PLC3 resulted in loss of M3R-mediated enrichment of PLC3 at plasma membrane.
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immunoblotted (IB) for either PLC3 N terminus (NT) or HA as in C. Representative Western blots shown were from four independent experiments. Error bars
represent S.E.
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presence of calcium alone or its activation by G was not
altered by these M3R constructs, indicating a specific effect on
Gq-dependent PLC activation (Fig. 5B). The effects of M3Ri2,
M3Ri3Na, and M3R/H8-CT on the potency and efficacy of
Gq-dependent PLC3 activation was tested under conditions
where the concentration ofGq was variedwith a fixed concen-
tration of receptor loop fragment (Fig. 5C). All of the loops
increased the potency ofGq asmarked by leftward shifts in the
[Gq]-PLC activity curves as well as increases in PLC activity at
the maximum [Gq] tested of 100 nM (Fig. 5C). To determine
whether the potentiation of Gq-dependent PLC activation is
specific to PLC3, Gq-dependent PLC2 activation was
examined for M3Ri2, M3Ri3Na, and M3R/H8-CT (Fig. 5D).
Although some potentiation of PLC2 activation was observed
by the fragments, it was significantly lower than that observed
for PLC3.
Binding of M3R Fragments to G Proteins—Some component
of the potentiation of Gq-dependent PLC activation may be
derived from an ability of the receptor fragments to bind G
proteins. The ability of the M3R fragments to bind Gq and
G was examined in the GST fusion protein binding assay
(Fig. 6A). M3Ri2, M3Ri3N, and M3R/H8-CT directly inter-
acted with purified Gq-GDP, whereas varying degrees of G
binding were observed for all M3R fragments except M3Ri1.
Binding of Gq to M3Ri3M and M3Ri3C could not be deter-
mined due to interference from the GST fusion proteins run-
ning at the samemolecular weight as Gq.M3Ri3Nwas further
dissected into six subfragments from residues 252–322 of
M3Ri3Na (Fig. 6B) to discriminate the binding determinants
for G proteins and PLC3. M3R fragments 1, 2, and 5 did not
bind PLC3, whereas fragments 3 and 4 bound PLC3 almost
as well as M3Ri3Na 252–322 (Fig. 6C). The binding was sub-
stantially reduced in fragment 6 (Fig. 6C), indicating that resi-
dues 310–314 ofM3R conferM3i3N the ability to bind PLC3.
In contrast, all six M3Ri3N constructs bound Gq to varying
degrees, whereas G binding to M3R fragments 3 and 4 was
consistent with previous reports (10) (Fig. 6C). In particular,
M3Ri3Na fragment 2 bound Gq but not PLC3 (Fig. 6C).
Fragments that bound Gq, G, and PLC3 did not bind to
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FIGURE 5. Intracellular loops of M3 muscarinic receptor specifically
enhance efficiency of Gq-dependent activation of PLC. A, [
3H]IP3 release
from [3H]PIP2-labeled vesicles due to PLC3 activation by Gq-GDP-AlF4
was
measuredas a functionofM3R loopconcentrationasdescribedunder “Exper-
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PLC3 activation was measured in the presence of calcium only, G12, or
Gq-GDP-AlF4
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PLC3 activation was measured as a function of [Gq-Mg-GDP-AlF4
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condition. Error bars represent S.E.
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Gs or Golf (Fig. 6D), supporting the specificity of the
interaction.
M3RFragment Binding to PLC3 Is Required for Potentiation
of Gq-dependent PLC3 Activation—To confirm that binding
of PLC3 is required for potentiation by M3R loops, we exam-
ined the ability of M3Ri3Na subfragments 2, 3, and 4 (from Fig.
6, B and C) to support potentiation of Gq-dependent PLC
activation (Fig. 7A). Fragment 3, which binds to PLC3, sup-
ported potentiation of PLC activation. Fragment 2, which did
not bind PLC3, did not support potentiation of Gq-depen-
dent PLC3 activation even though Gq binding remained
intact (Fig. 6C). This suggests thatwithinM3Ri3NPLC3 bind-
ing is necessary for potentiating PLC3 activation in the pres-
ence of Gq-GDP-AlF4. Surprisingly, fragment 4, which over-
laps with fragment 3 and binds Gq and PLC3, did not
potentiate Gq-dependent activation. These data suggest that
binding of PLC3 to the M3R loop is required but is not suffi-
cient to support potentiation of PLC activation.
Next we examined how deletion of the PLC3 PDZ ligand
may affect potentiation. Deletion of the PLC3 PDZ ligand
decreased but did not eliminate binding to M3Ri3Na (Fig. 4D).
There was a small but significant difference between PLC3
and PLC3PDZ with respect to M3Ri3Na-dependent poten-
tiation of Gq activation (Fig. 7B). Removal of PLC3 PDZ
ligand did not affect PLC3 activation by Ca2 or by Gq in the
absence of added M3R fragment (Fig. 7C).
Analysis of PLC3 binding toM3Ri3Na fragments 3, 4, and 6
suggested that residues 310–314were critical binding determi-
nants for PLC3. These amino acids were substituted individ-
ually with alanine as we sought to identify key residues for
PLC3 binding (Fig. 7D). Although pulldown of purified
PLC3 was decreased in all alanine mutants, mutants W313A
and H311A/W313A exhibited the most severe binding defects.
Having identified PLC3 binding determinants at i3N of
M3R (Fig. 7D) and M3R binding determinants on PLC3 (Fig.
4D), we examined how these domains may interact in modify-
ing potentiation of Gq-dependent PLC3 activation. The
interaction between thePDZmutation in PLC and the F312A
and W313A mutations in M3Ri3Na were investigated using
purified components. The W313A and F312A mutations in
M3Ri3Na inhibited their ability to potentiate activation of
PLC3PDZ by Gq (Fig. 7E). The decrease in potentiation
trended with the degree of decreased binding. The W313A
mutation inhibited potentiation to a greater extent than F312A
(although thesewere not statistically different fromeachother).
Overall these data support the idea that these specific protein-
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1, residues 252–273; 2, residues 274–294; 3, residues 295–322; 4, residues 289–314; 5, residues 262–285; 6, residues 286–309. C, binding site mapping for
PLC3, Gq, and G at M3Ri3N residues 252–322. To map binding sites for PLC3 (top), Gq (middle), or G (bottom), GST fusion proteins as described in B
wereused in apulldownassay. RepresentativeWesternblots shownwere each from two independent experiments.D, bindingof PLC3anddifferent isoforms
of G protein  subunits (Gq, Gs-long, and Golf) to M3Ri3Na fragments 3 and 4 was tested. Results were analyzed by Western blot. Representative Western
blots are shown from three independent experiments. Fractions of original inputwere loaded in the leftmost lanes. Sampleswere also immunoblotted (IB) with
anti-GST antibodies to validate loading equal amounts of protein.
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protein interactions between M3R and PLC regulate Gq-de-
pendent activation of PLC.
DISCUSSION
Here we demonstrate that PLC3 binds directly to the M3
muscarinic receptor intracellular surface and that this binding
can alter Gq-dependent PLC activation. Our model is
depicted in Fig. 8. In the inactive state, M3R binds to the C
terminus of PLC3, resulting in displacement of theC terminus
from the remainder of the PLC enzyme. This places PLC3 in
close spatial proximity to both its substrate, PIP2, and its acti-
vator, Gq. Upon receptor activation, Gq, which is either pre-
bound or recruited to the receptor, can efficiently activate the
M3R-boundPLC.Additionally,M3R activation recruits PLC3
to the receptor by either direct binding to the receptor or Gq-
GTP or a cooperative interaction of both.
We propose that this interaction serves a number of func-
tions. 1) Binding to M3R localizes PLC to the plasma mem-
brane where it has local access to its PIP2 substrate. This would
allow for spatial regulation of the effector reaction to the vicin-
ity of the receptor. 2) Binding to the M3R increases signaling
efficiency by increasing the effective local concentrations of
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FIGURE 7. Residues 309–314 of M3Ri3N and PDZ ligand of PLC3 are determinants for M3Ri3N-mediated potentiation of PLC3 activation. A, to
identify M3Ri3Na residues that contribute to the potentiation of Gq-dependent PLC3 activation, constructs M3Ri3Na, M3Ri3Na 2, M3Ri3Na 3, andM3Ri3Na
4were tested. The phospholipase C assay and data analysis were performed as in Fig. 5. A representative plot from four independent experiments is shown. B,
M3R-mediated potentiation of PLC3 activation was compared between PLC3 variants (PLC3 FL, 1–1234; PLC3PDZ, 1–1230) at 30 and 60 nM M3Ri3Na.
*, p	 0.05, paired Student’s t test from seven independent experiments. Coomassie staining of purified PLC3 proteins (1.5g each) is shown on the right. C,
PLC3 activation by Ca2 only or Gq was tested for purified PLC3 constructs. The data were compiled from seven independent assays. D, within M3Ri3Na
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mutant proteins were partially purified by GST-glutathione affinity chromatography. A representative Western blot from three independent experiments is
shown. Coomassie staining of each loaded GST fusion protein is shown on the bottommost panel. E, each M3Ri3Na variant was tested at 30 nM. * denotes
significantly different (p	 0.05) relative to i3WT-PLC3 FL. Data were compiled from at least four independent experiments. Coomassie staining of M3Ri3Na
WT (i3wt), M3Ri3Na F312A (i3FA), andM3Ri3NaW313A (i3WA) proteins (1.5g each) that were purified using His6-nickel affinity is shown on the left. Error bars
represent S.E. IB, immunoblot.
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activated Gq and PLC3. 3) Binding of PLC3 to M3R
increases its intrinsic capacity to be activated by Gq via an
allosteric mechanism.
Direct interactions between Gq and the M3R C terminus
have been suggested to account for the ability of M3R to pre-
vent the lateral mobility of Gq and alter M3R signaling effi-
ciency (6). Additionally, agonist-independent cross-links
between M3Ri2 and Gq have been identified, suggesting the
existence of preformed M3R-Gq complexes (29). Our data
showing direct interactions between Gq and M3R intracellu-
lar loops and C terminus are consistent with these data.
Another mechanism to control signaling efficiency by mus-
carinic receptors is through the GTPase-accelerating function
of PLC thought to kinetically scaffold Gq to a GPCR (19, 20).
Here we show a direct physical scaffolding of the effector PLC
to a GPCR that may contribute to signaling efficiency. It is also
possible that this physical scaffolding relates to kinetic scaffold-
ing, but this remains to be determined.
About half of Gq-coupled receptors have a C-terminal PDZ
ligand motif (5, 22, 41). The M3 muscarinic receptor does not
have a C-terminal PDZ ligand motif that would allow a PDZ
scaffold to mediate an interaction with PLC (42). Although
the M3R intracellular surface bears no homology to canonical
PDZ-binding domains, M3Ri3 directly binds PLC3 in a PDZ-
dependent fashion. Thus, this M3R-PLC3 interaction repre-
sents a non-canonical version of the highly organized PLC sig-
naling thatmanyGq-coupled receptorsmay require to properly
regulate phosphoinositide metabolism (5).
Previous studies of PLC plasmamembrane binding suggest
that the C-terminal domain of PLC isoforms may participate
in an ionic interactionwith the negatively charged inner surface
of the PM to drive partial membrane association (35, 43–46).
The data here, in combination with others, show that PLC3
does not associate with the plasma membrane unless M3R is
coexpressed (Fig. 1, C and D) (35). Additionally, the PLC3 C
terminus alone can interactwithmembranes (Fig. 2B) (35), sug-
gesting that this membrane binding determinant is masked in
the full-length enzyme. Binding of the C terminus by M3R
could expose these determinants to promote interactions with
the plasma membrane. Because M3R expression enhances PM
localization of the isolated PLC3 CT, a direct tethering to the
receptor must underlie part of the mechanism and could work
in combination with unmasking from the folded holoenzyme
(Fig. 8).
A surprising result was that fragments of M3R altered the
efficacy and potency of Gq-dependent PLC activation, imply-
ing a role of the M3R-PLC binding interaction in something
other than simple scaffolding. The distal C-terminal domain of
PLC3 has been suggested to coordinate interactions with the
membrane and the N terminus of Gq so that optimum PLC3
activation could be attained (45, 46). An intact PLC3 C-termi-
nal domain is coincidentally required for PLC3 binding to
M3R (Figs. 3, C andD, and 4D) and its potentiation of Gq-de-
pendent PLC3 activation (Fig. 7, B and E). Receptor binding
could impart another level of allosteric control on the PLC C
terminus.
The recent crystal structure of the 2-adrenergic receptor
complex with Gs suggests that there is little space for other
interactions with a monomeric receptor during G protein acti-
vation (47), but such interactions could be imagined in the con-
text of higher order GPCR dimers or oligomers. Biochemical
evidence using disulfide cross-linking showed that M3R could
form homodimers (48). Recent studies using resonance energy
transfer techniques (49, 50) suggest thatM3Rmay actually exist
as a dynamic mixture of dimers and rhombic tetramers.
Although we identified residues 294–322 of M3Ri3 as a
PLC3-binding element necessary for potentiating Gq-de-
pendent PLC3 activation, this element is within an apparently
expendable region of M3R 274–469 for carbachol-stimulated
total inositol phosphate production (40, 51). There are a few
possible explanations for this. PLC3 binding by M3Ri3 may
reflect a spatially and/or temporally restricted event that is dif-
ficult to detect in global inositol phosphate assays, or multiple
contacts may be involved in the interaction, and disruption of
one of them is insufficient to completely disrupt binding of PLC
to M3R and dramatically alter signaling efficiency in cells.
The M3R intracellular surface itself is likely conformation-
ally flexible, and activation of M3R led to increased binding of
PLC to the receptor. PLC3 and Gq bound more strongly to
M3Ri3Na (252–322) compared with the larger fragment
M3Ri3N (252–389) (Fig. 4C). One could envision a model
where receptor activation coordinates how binding sites on
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FIGURE 8. M3R interaction with PLC3 determines PLC3 signaling effi-
ciency. M3R binding to PLC3 localizes PLC3 at the plasma membrane via
the C-terminal tail of PLC3 and the intracellular loops and C-terminal tail of
the receptor. Thismay result in an unfolding of the PLC3 enzyme to result in
a more optimal interaction with G protein and substrate PIP2. Upon receptor
activation, more PLC3 is recruited from the cytosol to the receptor. Gq
either prescaffolded to the receptor (not depicted) or recruited by collision
coupling can then interact with the scaffolded PLC. PLC recruitment after
activation could be due to direct interactions with activated Gq, M3R, or
both. EF, EF hands; XY, X and Y catalytic cores.
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each intracellular loop become exposed to conformationally
maximize Gq-PLC coupling.
In summary, our studies define a novel PDZ-dependent
interaction between theM3muscarinic receptor and its signal-
ing effector, PLC3. Receptor expression drives PLC3 local-
ization at the plasma membrane and enhances the efficiency of
Gq signaling. These results translate into a mechanism for
how the GPCR-effector interactions could fine-tune signaling
beyond stimulating guanine nucleotide exchange.
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